Hybrid Nanoparticles for Haloperidol Encapsulation: Quid Est Optimum?
- Supplementary File 1:
ZIP-Document (ZIP, 211 KiB)
Filippov, S.K.; Khusnutdinov, R.R.; Inham, W.; Liu, C.; Nikitin, D.O.; Semina, I.I.; Garvey, C.J.; Nasibullin, S.F.; Khutoryanskiy, V.V.; Zhang, H.; Moustafine, R.I. Hybrid Nanoparticles for Haloperidol Encapsulation: Quid Est Optimum? Polymers 2021, 13, 4189. https://doi.org/10.3390/polym13234189
Filippov SK, Khusnutdinov RR, Inham W, Liu C, Nikitin DO, Semina II, Garvey CJ, Nasibullin SF, Khutoryanskiy VV, Zhang H, Moustafine RI. Hybrid Nanoparticles for Haloperidol Encapsulation: Quid Est Optimum? Polymers. 2021; 13(23):4189. https://doi.org/10.3390/polym13234189
Chicago/Turabian StyleFilippov, Sergey K., Ramil R. Khusnutdinov, Wali Inham, Chang Liu, Dmitry O. Nikitin, Irina I. Semina, Christopher J. Garvey, Shamil F. Nasibullin, Vitaliy V. Khutoryanskiy, Hongbo Zhang, and Rouslan I. Moustafine. 2021. "Hybrid Nanoparticles for Haloperidol Encapsulation: Quid Est Optimum?" Polymers 13, no. 23: 4189. https://doi.org/10.3390/polym13234189